Dr. Puvvada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
University of Arizona Cancer Center
Tucson, AZ 85724- Is this information wrong?
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2012
University of North Carolina HospitalsResidency, Internal Medicine, 2006 - 2009
University of South Florida College of MedicineClass of 2006
Certifications & Licensure
NC State Medical License 2009 - 2024
AZ State Medical License 2012 - 2019
Clinical Trials
- Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL Start of enrollment: 2012 Aug 31
- Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Start of enrollment: 2013 Dec 05
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Publications & Presentations
PubMed
- 17 citationsEfficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.Funda Meric-Bernstam, Vicky Makker, Ana Oaknin, Do-Youn Oh, Susana Banerjee, Antonio González-Martín, Kyung Hae Jung, Iwona Ługowska, Luis Manso, Aránzazu Manzano, Boh...> ;Journal of Clinical Oncology. 2024 Jan 1
- 7 citationsThe mechanism of cancer drug addiction in ALK-positive T-Cell lymphomaSoumya Sundara Rajan, Amit Dipak Amin, Lingxiao Li, Delphine Rolland, Haiquan Li, Deukwoo Kwon, Mercedes F. Kweh, Artavazd Arumov, Evan R. Roberts, Aimin Yan, Venkates...> ;Oncogene. 2020 Mar 5
- 22 citationsPhase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma., , , , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2018 Dec 15
- Join now to see all
Journal Articles
- Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/vincristine in Relapsed/refractory Aggressive B-cell LymphomaDaniel Persky, Soham Puvvada, Catherine Spier, Gregory Monohan, Ari VanderWalde, Daruka Mahadevan, Clinical Cancer Research
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
